Ann: Creso signs distribution agreement in Switzerland - CannaQIX, page-11

these are fair points - but I think bigger issue is that we all appreciate revenues from medical cannabis space will take some time to achieve for all players - including Canadian names that now have market cap in the billions in some instance

they issue is however who can deliver some incomes before that - MXC for instance has some neutraceuticals/face creams

CPH is working on vet products for instance

CPH now has several of these "interim" initiatives in place and while individually they maybe small, they all have some potential and collectively demonstrate company appreciates it needs to deliver results along the way

AC8 I think remains pic of the sector but to dismiss any of the names because they don't have a well defined revenues short term is maybe not the point at this stage - The target markets in pain management are so large that I really think you give the proactive names the benefit of the doubt for now and see which ones can deliver over next 12 months